REPRINTED WITH PERMISSION OF EFIC EJP: 27 (2023): 4453: A systematic review and meta-analysis of neuropathicpain associated with coronavirus disease 2019-Reference-Cited by-同舟云学术

REPRINTED WITH PERMISSION OF EFIC EJP: 27 (2023): 4453: A systematic review and meta-analysis of neuropathicpain associated with coronavirus disease 2019

Published:2023-05-05 Issue:1 Volume:24 Page:1-11
ISSN:1640-324X
Container-title:BÓL
language:
Short-container-title:

Author:

Di Stefano Giulia¹,Falco Pietro¹,Galosi Eleonora¹,Di Pietro Giuseppe¹,Leone Caterina¹,Truini Andrea¹

Affiliation:

1. Department of Human Neuroscience, Sapienza University, Rome, Italy

Abstract

Background and objective: Neuropathic pain is an occasionally reported complication of coronavirus disease 2019(COVID-19) that has received increased attention in scientific literature. In this systematic review and meta-analysis, weaimed to provide information on the frequency of neuropathic pain associated with COVID-19. Databases and data treatment: We systematically reviewed and analysed literature regarding neuropathic pain associatedwith COVID-19. Literature searches were conducted in PubMed, EMBASE and Cochrane Library databases. We consideredprospective and retrospective studies published up until September 2022 (limitations included English language, full-textpublications and studies including at least 10 patients). A random effects meta-analysis was performed and heterogeneityand publication bias were assessed. Results: We identified 149 studies. We included 17 studies in the systematic review, and six studies reporting the frequencyof neuropathic pain in the acute/ subacute phase of COVID-19 in the meta-analysis. The estimated frequency of neuropathicpain ranged between 0.4 and 25%. Forest plot analysis showed that the random effect overall frequency was 10% (95%confidence interval: 515%), with a high level of heterogeneity (Chi2 = 104; Tau2 = 0.004; df = 5; I2 = 95%; test for overalleffect: Z = 3.584; p < 0.0005). The overall risk of bias was moderate in all studies selected, particularly due to the poordescription of neuropathic pain diagnostic criteria. Conclusions: The pooled estimated frequency of neuropathic pain associated with COVID-19 should be considered withcaution due to the high heterogeneity across studies and the poor description of the neuropathic pain diagnostic criteriaapplied. Significance: Emerging evidence supports the development of neuropathic pain as a complication of COVID-19. However,longitudinal studies enrolling consecutive patients with COVID-19 that detail the diagnostic criteria for neuropathic pain areneeded to better assess the frequency of this condition.

Publisher

Index Copernicus

Subject

Geology,Ocean Engineering,Water Science and Technology

Reference58 articles.

1. Abrams R.M.C., Simpson D.M., Navis A. et al.: Small fiber neuropathyassociated with SARS-CoV-2 infection. Muscle & Nerve 2022; 65(4):440443. https:// doi.org/10.1002/mus.27458.

2. Aksan F., Nelson E.A., Swedish K.A.: A COVID-19 patient with intenseburning pain. Journal of Neurovirology 2020; 26(5): 800801. https://doi.org/10.1007/s13365-020-00887-4.

3. Attal N., Martinez V., Bouhassira D.: Potential for increased prevalence ofneuropathic pain after the COVID-19 pandemic. Pain Reports 2021; 6(1):e884. https://doi.org/10.1097/pr9.0000000000000884.

4. Balcom E.F., Nath A., Power C.: Acute and chronic neurological disordersin COVID-19: Potential mechanisms of disease. Brain 2021; 144(12):35763588. https://doi.org/10.1093/brain/awab302.

5. Bauer L., Laksono B.M., De Vrij F.M.S. et al.: The neuroinvasiveness,neurotropism, and neurovirulence of SARS-CoV-2. Trends inNeurosciences 2022; 45: 358368. https://doi.org/10.1016/j.tins.2022.02.006.